Markets
In a report issued on April 26, Richard Newitter from Leerink Partners maintained a Buy rating on Inspire Medical Systems (INSP – Research Report). The company’s shares closed last Wednesday at $242.23, close to its 52-week high of $252.25.
According to TipRanks.com, Newitter is a 5-star analyst with an average return of 28.6% and a 71.1% success rate. Newitter covers the Healthcare sector, focusing on stocks such as Zimmer Biomet Holdings, Organogenesis Holdings, and Intuitive Surgical.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Inspire Medical Systems with a $257.00 average price target, implying a 9.1% upside from current levels. In a report issued on April 22, Robert W. Baird also maintained a Buy rating on the stock with a $260.00 price target.
Atricure (ATRC)
In a report issued on April 27, Danielle Antalffy from Leerink Partners maintained a Buy rating on Atricure, with a price target of $78.00. The company’s shares closed last Wednesday at $69.85, close to its 52-week high of $72.07.
According to TipRanks.com, Antalffy is a 5-star analyst with an average return of 25.9% and a 70.9% success rate. Antalffy covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies, Tandem Diabetes Care, and Edwards Lifesciences.
Atricure has an analyst consensus of Strong Buy, with a price target consensus of $75.57, representing a 15.3% upside. In a report issued on April 27, Oppenheimer also maintained a Buy rating on the stock with a $75.00 price target.
Oppenheimer Reaffirms Their Hold Rating on Shockwave Medical (SWAV) analystratings.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from analystratings.com Daily Mail and Mail on Sunday newspapers.
Home / Top News / Inspire Medical Systems, Inc. Announces Exclusive Distribution Agreement with Japan Lifeline Co., Ltd to Commercialize Inspire Therapy in Japan
Inspire Medical Systems, Inc. Announces Exclusive Distribution Agreement with Japan Lifeline Co., Ltd to Commercialize Inspire Therapy in Japan
Reimbursement Review of Inspire Therapy Completed by Japan Ministry of Health Labour and Welfare (MHLW); National Health Insurance Payment Listing Expected in June 2021
Initial Inspire Therapy Implants in Japan Anticipated to Occur in Second Half of 2021
MINNEAPOLIS, Minn., April 26, 2021 (GLOBE NEWSWIRE) Inspire Medical Systems, Inc. (NYSE: INSP) (“Inspire”), a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea (“OSA”), today announced an exclusive distribution agreement with Japan Lifeline Co., Ltd. (“JLL”), an independent full-service distributor of m
Inspire Medical Systems (INSP)
In a report issued on April 22, Michael Polark from Robert W. Baird maintained a Buy rating on Inspire Medical Systems, with a price target of $260.00. The company’s shares closed last Friday at $227.68, close to its 52-week high of $252.25.
According to TipRanks.com, Polark is a 4-star analyst with an average return of 17.3% and a 72.4% success rate. Polark covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies, Irhythm Technologies, and Intuitive Surgical.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Inspire Medical Systems with a $257.00 average price target.